MedTech Dive December 6, 2023
The company outlined its long-term growth expectations and confirmed that it has no plans to separate its medtech and pharma segments.
After spinning out its consumer health business, Johnson & Johnson has no plans to do the same with its medtech business. J&J CEO Joaquin Duato told investors on Tuesday that “we all firmly believe that medtech and pharma belong together.”
The company also outlined long-term financial expectations for each of its segments.
Here are 5 takeaways from J&J’s investor day:
1. J&J has no plans to spin out its medtech business
Citi analyst Joanne Wuensch kicked off the Q&A session at the event with a big question: Is J&J’s recent spinoff of its consumer business just phase...
Today's Sponsors
Today's Sponsor
Topics: Medical Devices